Literature DB >> 15524068

Treatment of brain metastases.

Teri Nguyen1, Lisa M Deangelis.   

Abstract

Brain metastases are a common complication of cancer, found in approximately 20% of patients at autopsy. The diagnosis is usually established by neuroimaging and carries a poor overall prognosis. Supportive therapies, such as corticosteroids, anticonvulsants, and anticoagulants, are necessary for most patients to address the common medical complications that often accompany brain metastases. These treatments often ameliorate symptoms and signs and improve neurologic function, but they require careful management to minimize their common toxicities. Definitive antitumor treatment may include whole-brain radiotherapy, surgery, stereotactic radiosurgery, and chemotherapy. A multimodal approach can yield prolonged survival of a year or more in some patients, particularly those with limited intracranial disease, high performance status, limited systemic cancer burden, young age, and certain tumor pathologies. However, even patients with poor prognostic factors can have some relief of neurologic symptoms and signs with the institution of therapy. Patients with recurrent brain metastases can also benefit from additional treatment, including all the modalities available at diagnosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15524068

Source DB:  PubMed          Journal:  J Support Oncol        ISSN: 1544-6794


  8 in total

1.  Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.

Authors:  S A Laurie; S Banerji; N Blais; S Brule; P K Cheema; P Cheung; N Daaboul; D Hao; V Hirsh; R Juergens; J Laskin; N Leighl; R MacRae; G Nicholas; D Roberge; J Rothenstein; D J Stewart; M S Tsao
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

Review 2.  Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options?

Authors:  S Morin-Ben Abdallah; A Wong
Journal:  Curr Oncol       Date:  2018-06-13       Impact factor: 3.677

3.  An approach for computer-aided detection of brain metastases in post-Gd T1-W MRI.

Authors:  Reza Farjam; Hemant A Parmar; Douglas C Noll; Christina I Tsien; Yue Cao
Journal:  Magn Reson Imaging       Date:  2012-04-20       Impact factor: 2.546

4.  Role of palliative radiotherapy in brain metastases.

Authors:  Ramesh S Bilimagga; S Nirmala; Karthik S Rishi; Mg Janaki; Arul Ponni; Ag Rajeev; Suman Kalyan
Journal:  Indian J Palliat Care       Date:  2009-01

5.  Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study.

Authors:  Sheng-Kai Liang; Meng-Rui Lee; Wei-Yu Liao; Chao-Chi Ho; Jen-Chung Ko; Jin-Yuan Shih
Journal:  Oncotarget       Date:  2018-05-04

6.  Could intracranial tumor volume predict prognosis of patients with brain metastases from esophageal carcinoma?

Authors:  Linlin Xiao; Qiang Lin; Mengzhu Hu; Yi Wang; Zhouguang Hui; Fengpeng Wu; Jun Wang
Journal:  Thorac Cancer       Date:  2022-03-15       Impact factor: 3.223

7.  Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.

Authors:  Petra Hoffknecht; Amanda Tufman; Thomas Wehler; Theo Pelzer; Rainer Wiewrodt; Martin Schütz; Monika Serke; Jan Stöhlmacher-Williams; Angela Märten; Rudolf Maria Huber; Nicolas J Dickgreber
Journal:  J Thorac Oncol       Date:  2015-01       Impact factor: 15.609

8.  Clinicopathological characteristics and prognosis of brain metastases in elderly patients with esophageal carcinoma.

Authors:  Yi Wang; Linlin Xiao; Jiandong Zhang; Xiaoyan Lv; Feng Cao; Min Zhao; Fengpeng Wu; Shaowu Jing; Jun Wang
Journal:  Thorac Cancer       Date:  2021-09-28       Impact factor: 3.500

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.